Please use this identifier to cite or link to this item:
Title: Selective targeting of the tumour vasculature.
Austin Authors: Chan, Lie S;Daruwalla, Jurstine;Christophi, Christopher 
Affiliation: Department of Surgery, University of Melbourne, Austin Health, Heidelberg, Victoria, Australia
Issue Date: 1-Nov-2008
Publication information: ANZ Journal of Surgery; 78(11): 955-67
Abstract: Selective targeting of the tumour vasculature in the treatment of solid organ malignancies is an alternative to conventional chemotherapy treatment. As the tumour progressively increases in size, angiogenesis or the formation of new vasculature is essential to maintain the tumour's continual growth and survival. Therefore disrupting this angiogenic process or targeting the neovasculature can potentially hinder or prevent further tumour expansion. Many anti angiogenic agents have been investigated with many currently in clinical trials and exhibiting varied results. Vascular disrupting agents such as the Combretastatins and OXi 4503 have shown promising preclinical results and are currently being examined in clinical trials.
Gov't Doc #: 18959693
DOI: 10.1111/j.1445-2197.2008.04712.x
Journal: ANZ Journal of Surgery
Type: Journal Article
Subjects: Angiogenesis Inhibitors.therapeutic use
Neoplasms.blood supply.drug therapy
Neovascularization, Pathologic.prevention & control
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Jun 24, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.